THE INST OF CANCER RESEARCH: ROYAL CANCER HOSPITAL has a total of 11 patent applications. It decreased the IP activity by 80.0%. Its first patent ever was published in 2013. It filed its patents most often in WIPO (World Intellectual Property Organization), United States and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and computer technology are IGNYTA INC, CELL PATHWAYS INC and LOXO ONCOLOGY INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 5 | |
#2 | United States | 3 | |
#3 | EPO (European Patent Office) | 2 | |
#4 | United Kingdom | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Computer technology | |
#4 | Organic fine chemistry | |
#5 | Measurement | |
#6 | Foods and drinks | |
#7 | Environmental technology |
# | Name | Total Patents |
---|---|---|
#1 | Linardopoulos Spyridon | 3 |
#2 | Barbeau Olivier Remi | 1 |
#3 | Gurden Mark | 1 |
#4 | Marais Richard | 1 |
#5 | Leung Leo | 1 |
#6 | Smith Graeme Cameron Murray | 1 |
#7 | Kalusa Andrew | 1 |
#8 | Huang Paul | 1 |
#9 | Williamson Chris | 1 |
#10 | Moore Andrew S | 1 |
Publication | Filing date | Title |
---|---|---|
WO2017118734A1 | Inhibitors of ataxia-telangiectasia mutated and rad3-related protein kinase (atr) for use in methods of treating cancer | |
US2015232462A1 | Fused heterocyclic compounds and their use | |
US2014045853A1 | Materials, methods, and systems for treating cancer |